Review of a new fully liquid, hexavalent vaccine: Hexaxim.

about

Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months.Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts

P2860

Q50047495-5D8F79CE-B754-4D04-AA4C-AB093AD00126 Q56380558-5B77B953-584B-4FA1-A3A0-DDD9BE972874

P2860

Review of a new fully liquid, hexavalent vaccine: Hexaxim.

Item

http://www.wikidata.org/entity/Q38084695

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Review of a new fully liquid, hexavalent vaccine: Hexaxim.

@en

type

Item

label

Review of a new fully liquid, hexavalent vaccine: Hexaxim.

@en

prefLabel

Review of a new fully liquid, hexavalent vaccine: Hexaxim.

@en

P1476

Review of a new fully liquid, hexavalent vaccine: Hexaxim.

@en

P2860

Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life

Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis.

New combination vaccines.

Vaccines for children: policies, politics and poverty.

Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates.

Correlates of protection induced by vaccination.

A DTaP-IPV//PRP∼T vaccine (Pentaxim): a review of 16 years' clinical experience.

Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria.

Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America.

Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants.

P304

575-593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2013.774368

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marta C Nunes

Shabir A. Madhi

P577

2013-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23441818

http://www.w3.org/2001/XMLSchema#string

Review of a new fully liquid, hexavalent vaccine: Hexaxim.

about

P2860

P2860

Review of a new fully liquid, hexavalent vaccine: Hexaxim.

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698